Skip to main content

Table 1 Treatment Contrasts

From: Gene expression profiling of long-lived dwarf mice: longevity-associated genes and relationships with diet, gender and aging

Contrast Symbol Treatment A Treatment B
snell5a Pit1dw/dwmales, age 4–6 months, n = 4 Pit1dw/?control males, age 4–6 months, n = 4
snell25a Pit1dw/dwmales, age 24–26 months, n = 3 Pit1dw/?control males, age 24–26 months, n = 3
ames5Ab Prop1df/dfmales, age 4–6 months, n = 5 Prop1+/+ control males, age 4–6 months, n = 5
ames13Ab Prop1df/dfmales, age 12–14 months, n = 5 Prop1+/+ control males, age 12–14 months, n = 5
ames25Ab Prop1df/dfmales, age 24–27 months, n = 5 Prop1+/+ control males, age 24–27 months, n = 5
ames3Bc Prop1df/dfmales, age 3 months, n = 3 Prop1+/+ control males, age 3 months, n = 5
ames6Bc Prop1df/dfmales, age 6 months, n = 3 Prop1+/+ control males, age 6 months, n = 5
ames12Bc Prop1df/dfmales, age 12 months, n = 3 Prop1+/+ control males, age 12 months, n = 5
ames24Bc Prop1df/dfmales, age 24 months, n = 3 Prop1+/+ control males, age 24 months, n = 5
little3c Ghrhrlit/litmales, age 3 months, n = 3 Ghrhrlit/+males, age 3 months, n = 3
little6c Ghrhrlit/litmales, age 6 months, n = 3 Ghrhrlit/+males, age 6 months, n = 3
little12c Ghrhrlit/litmales, age 12 months, n = 3 Ghrhrlit/+males, age 12 months, n = 3
little24c Ghrhrlit/litmales, age 24 months, n = 3 Ghrhrlit/+males, age 24 months, n = 3
GHR-KOd GHR(-/-) males, age 42 days, n = 3 wild type males, age 42 days, n = 3
GHR-KI1d GHR knock-in mutant 569, males, age 42 days, n = 3 wild type males, age 42 days, n = 3
GHR-KI2d GHR knock-in mutant 391, males, age 42 days, n = 3 wild type males, age 42 days, n = 3
B6e C57BL/6J (B6) females, age 2 months, n = 3 (20–30% reduced serum IGF-I) C3H/HeJ (C3H) females, age 2 months, n = 3
Genderf wild type females, age 3–6 months, n = 6 wild type males, age 3–6 months, n = 6
cr(2,6)g 4 months of 30% calorie restriction, initiated age 2, tissue harvest age 6, wild type females, n = 8 wild type littermates of treatment A fed on control diet, n = 7
cr(2,6)dfg 4 months of 30% calorie restriction, initiated age 2, tissue harvest age 6, Prop1df/dffemales, n = 8 Prop1df/dffemale littermates of treatment A with control diet, n = 8
cr(20,22)h 2 months of 40% calorie restriction, initiated age 20, tissue harvest age 22, strain B6C3F1 males, n = 4 strain B6C3F1 males fed on control diet, tissue harvest age 22, n = 4
cr(5,22)h 17 months 40% calorie restriction, initiated age 5, tissue harvest age 22, strain B6C3F1 males, n = 4 strain B6C3F1 males fed on control diet, tissue harvest age 22, n = 4
meth metformin, 2100 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
met(db/db)i metformin, 400 mg/kg, C57BL/ksj – db/db males, n = 5 placebo, C57BL/ksj – db/db males, n = 5
gliph glipizide, 1050 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
gmh metformin & glipizide, met dose: 1050 mg per kg diet, glip dose: 525 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
rosh rosiglitazone, 80 mg per kg diet, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
soyh soy isoflavone extract, 0.25%, tissue harvest age 22, strain B6C3F1 males, n = 4 control diet, tissue harvest age 22, strain B6C3F1 males, n = 4
lowfat1j 4.5% fat diet by weight, congenic C57BL/6J males, n = 3 21% fat diet by weight, congenic C57BL/6J males, n = 3
lowfat2k very low fat diet, strain C57BL/6J males, n = 5 normal diet, strain C57BL/6J males, n = 5
agel age 4 months, wild type, n = 4 age 32 months, wild type, n = 4
  1. Each contrast corresponds to a test of differential expression and set of genes identified as significantly upregulated or downregulated. The A column lists treatments known or hypothesized to be associated with increased lifespan. The B column lists comparable control treatments associated with normal lifespan. All contrasts were of the form A – B, such that upregulated genes exhibit increased expression in treatment A (relative to treatment B) while downregulated genes exhibit decreased expression in treatment A (relative to treatment B). The RNA source for all treatments was liver and the value n refers to the number of independent biological replicates available for each treatment.
  2. aGSE3129, MG-U74Av2, Boyleston et al. [20]
  3. bGSE3150, MG 430 2.0, Boyleston et al. [20]
  4. cEMEXP153, MOE 430A, Amador-Noguez et al. [19]
  5. dGSE988, MG-U74Av2, Rowland et al. [26]
  6. eGSE5959, MG-U74Av2, Adamo et al. [27]
  7. fEMEXP347, MOE 430A, Amador-Noguez et al. [87]
  8. gGSE1093, MG-U74Av2, Tsuchiya et al. [24]
  9. hGSE2431, MG-U74Av2, Dhahbi et al. [28]
  10. iEMEXP490, MG-U74Av2, Heishi et al. [88]
  11. jGSE363, MG-U74Av2, Recinos et al. [89]
  12. kGSE3889, MG 430 2.0, Flowers et al. [90]
  13. lEMEXP839, MG 430 2.0, Niedernhofer et al. [91]
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us